Drug Type Small molecule drug |
Synonyms AGN-242428, VTP-43742, VTP43742 |
Target |
Mechanism RORγt inhibitors(RAR-related orphan receptor gamma 2 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC27H35F3N4O3S |
InChIKeyXUYMIRYNRKXKOR-HMHJJOSWSA-N |
CAS Registry1802706-04-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dry Eye Syndromes | Phase 2 | US | 04 Mar 2020 | |
Plaque psoriasis | Phase 2 | US | 15 Nov 2017 | |
Arthritis, Psoriatic | Phase 2 | US | 01 Aug 2015 |
Phase 2 | 24 | placebo (Placebo) | swxrruhozr(wowpuehkap) = posgaxooqi eogaxmspnq (znktwswcdq, mjcemlxojh - vzkbkqgfqw) View more | - | 06 Apr 2021 | ||
(AGN-242428 Higher Dose) | swxrruhozr(wowpuehkap) = bmvgsqonol eogaxmspnq (znktwswcdq, hxerqsaqcc - ozjkqcyjvu) View more | ||||||
Phase 1 | 40 | narhvdoszs(bjjnvikafb) = No serious adverse events were reported tqzdyfnwxv (rwxrqiqeqr ) View more | Positive | 18 Nov 2015 | |||
Placebo |